Methods and materials for improved immunoassays using synthetic antigens
AssigneeThe Terasaki Innovation Center
InventorsNeng Jen Remi Shih, Thoa Nong, Jar-How Lee
Life of this patent
Estimating the term…
Abstract
Described herein are materials and methods for improved immunoassays using synthetic antigens in which samples are treated to bind antibodies specific to histidine polymer antigens.
Claims46
A method of screening a biological sample for antibodies that specifically bind a target antigen by:
- obtaining a biological sample from a subject,
- subjecting the biological sample to histidine polymers in order to block or remove anti-poly-histidine antibodies from the biological sample,
- contacting the target antigen with the biological sample, and
- detecting binding of antibodies in said biological sample to the target antigen.
A method of screening for antibodies that specifically bind a target antigen comprising preparing a panel comprising a solid-phase substrate having said target antigen immobilized or attached thereto;
- obtaining a biological sample from a subject,
- subjecting the biological sample to histidine polymers to block or remove anti-poly-histidine antibodies from the serum sample,
- contacting the panel with the biological sample, and
- detecting binding of antibodies in said biological sample to the target antigen.
(canceled)
(canceled)
A method of screening for antibodies that specifically bind a target antigen comprising preparing a panel comprising a solid-phase substrate having a target antigen immobilized thereon and at least one other antigen selected from the group consisting of those consisting of antigens comprising at least two contiguous histidine peptides and fusion proteins with at least two contiguous histidine peptides and fusion peptides selected from the group of consisting of fusion proteins of a Human leukocyte antigen (HLA), and antigens selected from the group consisting of HIV, Lyme disease, syphilis, rotavirus and SARS associated coronavirus antigens with at least two contiguous histidine peptides,
- obtaining a biological sample from a subject,
- contacting the panel with the serum sample,
- detecting binding of antibodies in said serum sample to the target antigen, and
- detecting binding of antibodies in said serum sample to the poly-histidine antigen.
A kit for screening for antibodies that specifically bind to a target antigen and/or to a poly-histidine antigen comprising a panel of solid-phase substrates wherein the panel comprises a solid phase substrate having a target antigen immobilized thereon and at least one other antigen selected from the group consisting of those comprising at least two contiguous histidine peptides, fusion proteins with at least two contiguous histidine peptides and fusion proteins of a Human leukocyte antigen (HLA), and antigens selected from the group consisting of HIV, Lyme disease, syphilis, rotavirus and SARS associated coronavirus antigens with at least two contiguous histidine peptides with at least 2 contiguous histidine peptides immobilized thereon.
A kit for removing antibodies that specifically bind to a poly-histidine antigen comprising a solid-phase substrate wherein an oligopeptide selected from the group consisting of those comprising at least two contiguous histidine peptides, fusion proteins with at least two contiguous histidine peptides and fusion proteins selected from the group of consisting fusion proteins of a Human leukocyte antigen (HLA), and antigens selected from the group consisting of HIV, Lyme disease, syphilis, rotavirus and SARS associated coronavirus antigens with at least 2 contiguous histidine peptides is immobilized thereon.
A kit comprising:
- a solid phase substrate to which a target antigen is immobilized,
- a solution comprising wherein an oligopeptide selected from the group consisting of those comprising at least two contiguous histidine peptides and fusion proteins selected from the group of consisting of fusion proteins of a Human leukocyte antigen (HLA), and antigens selected from the group consisting of HIV, Lyme disease, syphilis, rotavirus and SARS associated coronavirus antigens with at least two contiguous histidine peptides, and
- a component capable of preventing non-specific antibody binding.
(canceled)
A lateral flow immunoassay device comprising a test strip having a first position at which a fluid sample is administered and a second position having a target antigen immobilized thereon upon which histidine polymers are immobilized between the first and second positions.
Dependencies are inferred from the claim text.